Scorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign

Scorpius Holdings Inc., an integrated contract development and manufacturing organization (CDMO), has announced that it expects to launch its first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024.

The commencement of mammalian cGMP campaigns marks a significant development as it opens new revenue streams for the company’s CDMO operations.

Jeff Wolf, CEO of Scorpius, remarked, “I am extremely proud of what our team has accomplished in a short period of time. Our manufacturing and quality teams have worked exceptionally hard to get our mammalian facilities operational in less than two years, well ahead of the typical timing for such complex buildouts. Scorpius is now extremely well-positioned to support a wide range of early-stage clinical programs.”

“Our facility’s design includes cleanrooms with mobile equipment, allowing for easily customized configurations to meet the specific needs of each project. Our strategy is to expand our scope of services as our clients advance their respective programs through clinical development. Looking ahead, Scorpius has already secured bookings for additional cGMP activities in the mammalian building for 2025, demonstrating the demand and confidence in our expanded capabilities,” concluded Mr. Wolf.